Epithalon
- Category
- Longevity & Anti-Aging
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic four-amino-acid peptide marketed for anti-aging and sleep, said to activate telomerase (the enzyme that rebuilds chromosome caps) and raise melatonin. Most evidence is from animals and cells, and nearly all human data is from one unreplicated Russian group. There are no large human safety trials, and switching on telomerase raises a theoretical cancer-growth risk. Not an approved US drug, and most supply is unregulated research-grade material.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Epithalon is a short synthetic peptide made of just four amino acids, originally developed from an extract of the pineal gland — the small brain structure that regulates your sleep-wake rhythm. It is studied primarily for its ability to activate telomerase, the enzyme that maintains telomeres — the protective caps on the ends of your chromosomes that shorten each time cells divide. This shortening is considered one of the fundamental mechanisms of biological aging.
How it works in the body
Activates telomerase, the enzyme that rebuilds telomeres (protective caps on chromosome ends that shorten with each cell division). By lengthening telomeres, it extends the number of times a cell can divide before becoming senescent. It also stimulates melatonin production from the pineal gland.
Research overview
Epithalon induced telomerase activity and telomere elongation in cultured human fetal fibroblasts. A small human study reported a 1.7-fold rise in urinary melatonin metabolite, without measuring sleep improvement. Antioxidant and immune effects are mainly preclinical. Research on epithalamin extract should be distinguished from studies of this synthetic peptide. Independent cell-culture research appeared in 2025.
Who researches Epithalon?
Commonly researched by
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People exploring sleep quality improvement
Researched for effects on sleep architecture, circadian rhythm, or sleep quality.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching longevity and anti-aging interventions
Studied for effects on aging pathways, cellular health, or lifespan extension.
People researching experimental oncology peptides
Studied for effects on cancer cell targeting or tumor biology in preclinical research.
Important considerations for
Those with Active cancer
ModerateTelomerase activation could theoretically promote cancer cell immortality, though evidence is mixed.
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data.
Safety & interactions
Do not use if
Active cancer
ModerateTelomerase activation could theoretically promote cancer cell immortality, though evidence is mixed.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(5)
Rated by level of concern
No large-scale safety studies in humans
High2025 review PMC11943447 (toxicology gap noted in Future Perspectives); FDA (no approval)
Theoretical risk: telomerase activation could accelerate pre-existing cancer
TheoreticalMechanism-based; animal antitumor data in 2025 review PMC11943447
Almost all human data from a single Russian research group (no independent replication)
High2025 review PMC11943447; author attribution confirmed across all cited PMIDs
Only the all-L stereoisomer studied
LowNo published D-isomer/alternative-stereoisomer studies identified
Quality of unregulated products sold online
HighFDA (not approved)
Interaction summary(6)
Rated by direction with this peptide
Exogenous melatonin
CautionTheoreticalEpithalon stimulates endogenous melatonin synthesis (confirmed ~1.6-fold in the 75-women trial), so adding oral melatonin is largely redundant and additive and could over-shift circadian phase or increase sedation.
Melatonergic mechanism, 2025 review PMC11943447
Thymalin (thymic peptide)
SynergisticLowCo-administered with Epithalon/epithalamin in Khavinson-Korkushko geroprotector cohorts (n~266) with reported additive longevity and immune benefit. Backed by actual human co-administration data, so Low rather than Theoretical.
Khavinson/Korkushko combination geroprotector studies
Standard cardiac therapy (antihypertensives / antianginals)
ProtectiveLowIn the Korkushko trials the pineal peptide (epithalamin EXTRACT, not the synthetic tetrapeptide) was added on top of unchanged standard cardiac therapy and improved cardiovascular outcomes with no adverse interaction reported. Direction reflects additive clinical benefit, not a pharmacological interaction.
Korkushko RCT, PMID 22451889 / PMID 17426848 (epithalamin extract)
Active malignancy / chemotherapy (oncologic setting)
CautionTheoreticalTelomerase-activating mechanism is theoretically undesirable in patients with pre-existing cancer; no human oncologic safety data exist, so avoid pending evidence.
Mechanism-based; telomerase data in 2025 review PMC11943447
CNS depressants / sedatives (benzodiazepines, alcohol)
CautionTheoreticalRaised endogenous melatonin could add modestly to sedation or next-morning grogginess when combined with other CNS depressants.
Melatonergic mechanism, 2025 review PMC11943447
Antidiabetic / glucose-lowering agents
CautionTheoreticalEpithalamin has been reported to normalize carbohydrate and lipid metabolism in aged subjects, giving a theoretical additive glucose-lowering effect that warrants monitoring in treated diabetics. Rated Theoretical: the abstract of PMID 17426848 centers on cardiovascular/functional-age outcomes and does not itself document the glucose/lipid normalization, so the metabolic premise rests on the broader epithalamin geroprotector literature.
Broader epithalamin geroprotector literature (Korkushko/Khavinson); PMID 17426848 is centered on CV/functional-age endpoints, not glucose metabolism
Known risks(5)
No large-scale safety studies in humans
Theoretical risk: telomerase activation could accelerate pre-existing cancer
Almost all human data from single Russian research group (no independent replication until 2025)
Only the all-L stereoisomer studied (7 other forms untested)
Quality of unregulated products sold online
Drug interactions(2)
Thymalin
Combined use in Khavinson geroprotective study (n=266) showed additive longevity benefits
Melatonin
Epithalon stimulates endogenous melatonin — exogenous melatonin may be redundant or additive
Research & benefits
Evidence base
- Evidence Level
- Mostly Preclinical
- Total Studies
- 100
- Human Studies
- 8
Mostly preclinical evidence, with small human studies of retinal outcomes and melatonin-related biomarkers. The cardiovascular mortality and larger geroprotection studies cited here used epithalamin extract, a different substance. Independent cell-culture research appeared in 2025.
Researched for(8)
Rated by confidence in the evidence
Telomerase activation
MediumHuman cell studies show telomeres lengthened about 33% and division continued past the normal limit.
Vinogradova/Khavinson, PMID 12937682; 2025 review PMC11943447
Lifespan extension (animal models)
MediumAnimal studies report lifespan effects; the SHR mouse study increased maximum lifespan 12.3% but did not increase mean lifespan.
Anisimov et al. SHR mice, PMID 14501183; 2025 review PMC11943447
Melatonin/circadian restoration
MediumA study involving 75 middle-aged women found a 1.7-fold rise in urinary melatonin metabolite in the treated low-melatonin group; sleep outcomes were not measured.
2025 review PMC11943447 (75-women sublingual trial confirmed); Korkushko epithalamin circadian studies
CV mortality reduction
LowA multi-year trial of the related pineal extract epithalamin found lower cardiac mortality in elderly patients.
Korkushko/Khavinson 15-yr follow-up RCT, PMID 22451889; PMID 17426848 (both epithalamin extract, not synthetic peptide)
Antitumor activity
LowAnimal data show fewer leukemias, though total tumor incidence was largely unchanged.
Anisimov SHR tumor incidence, PMID 14501183 (total tumor incidence unchanged, only leukemia reduced); 2025 review PMC11943447 (HER-2/neu data)
Retinal protection
MediumA 162-patient trial reported positive effects in about 90% of retinitis pigmentosa cases.
Retinitis pigmentosa trial, PMID 12195242; 2025 review PMC11943447
Antioxidant protection
LowCell and animal studies show activation of Nrf2 and antioxidant enzymes like SOD and catalase.
2025 review PMC11943447 (Drosophila, CBA mice, human fibroblast Nrf2 data)
Neuroprotection
LowLab and animal studies show less neuronal DNA damage and improved dendritic structure.
2025 review PMC11943447 (SH-SY5Y, NB7, fibroblast-derived neurons, rat cortex)
Benefits(9)
Telomerase activation
Lifespan extension (animal models)
Melatonin/circadian restoration
CV mortality reduction
Antitumor activity
Retinal protection
Antioxidant protection
Neuroprotection
Immune modulation
Key studies(5)
Khavinson VKh et al.
Bull Exp Biol Med
2003
Reactivated telomerase in telomerase-negative human fibroblasts
Anisimov VN et al.
Biogerontology
2003
Maximum lifespan increased 12.3%; mean lifespan and total tumor incidence were unchanged. Leukemia development was reduced sixfold.
Khavinson V et al.
Neuro Endocrinol Lett
2002
Positive effects in 90% of 162 patients
Korkushko OV et al.
Bull Exp Biol Med
2006
Epithalamin extract, not synthetic epitalon, was associated with 28% lower overall mortality and twofold lower cardiovascular mortality over 12 years.
Al-Dulaimi S et al.
Biogerontology
2025
First independent confirmation of telomerase mechanism
What research suggests over time
Weeks 2-4
Russian clinical useA small study reported changes in urinary melatonin metabolite and circadian-gene expression; improvement in sleep quality was not established.
Months 2-3
Russian observationalMelatonin pulse normalization and antioxidant enzyme upregulation reported in observational studies.
Long-term
Preclinical + observationalAnimal data shows ~10-25% lifespan extension; human longevity claims are observational and Russia-only.
Regulation & availability
Why researchers look at it
Cultured human fibroblast studies reported telomerase activation and telomere elongation. Animal lifespan findings vary; the SHR study increased maximum lifespan but not mean lifespan. The 12-year mortality trial used epithalamin extract, not synthetic epitalon. Independent cell-culture research appeared in 2025. If broader research validates these results, Epithalon could become relevant to preventing age-related decline.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- Epithalon is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Epithalon; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
- WADA status
- Epitalon is not named on the 2026 WADA Prohibited List. S0 prohibits pharmacological substances with no current governmental approval for human therapeutic use, unless another section applies; athletes should obtain a compound-specific determination from their anti-doping organization.
- Prescribability
- Epithalon is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Epithalon; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
- Availability
- Unapproved in the US. Its nomination was withdrawn, and it is absent from current 503A Category 1 and the final bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. A clinic's offering does not show that it meets those conditions.
International status
EU
Not approved
US
Epithalon is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing Epithalon; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
Russia
Used clinically (St. Petersburg Institute of Bioregulation)
Regulatory timeline(3)
- 2023-09FDA Category 2Restricted from compounding
- 2025First independent replicationAl-Dulaimi et al. confirmed telomerase mechanism (non-Russian group)
- 2026-10-28HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of epitalon acetate under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.
Sources & FAQs
Research sources(5)
- Epithalon induces telomerase activity and telomere elongation in human somatic c
- Effect of Epitalon on biomarkers of aging, life span and tumor incidence in SHR
- Epitalon improves eye retina condition in retinitis pigmentosa
- Geroprotective effect of epithalamine in elderly subjects
- Epitalon increases telomere length via telomerase or ALT activity
Frequently asked questions(5)
Is Epithalon safe?
Human safety is inadequately characterized, especially for subcutaneous injection. FDA identifies potential immunogenicity and impurity risks and found no clinical studies assessing safety.
How is it administered?
Subcutaneous or intramuscular injection in short courses. Intranasal and sublingual routes have also been studied.
Does it cause cancer?
Preclinical evidence suggests antitumor properties. 2025 study found ALT pathway in cancer cells instead of telomerase. Theoretical concern remains.
How strong is the evidence?
Compelling preclinically but limited clinically. Most human data from single Russian group. First independent replication 2025.
Can I legally obtain it in the US in 2026?
Epitalon is not FDA-approved and is not on FDA's compounding list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound epitalon acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle, dispensed in intermittent courses, made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Unregulated products sold online are outside the policy.